Ridogrel is an orally active, potent and specific combined thromboxane synthase inhibitor and thromboxane A2 receptor ( thromboxane/prostaglandin endoperoxide receptor) antagonist. Ridogrel is a potent antiplatelet agent.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
European journal of gastroenterology & hepatology, 13(4), 397-400 (2001-05-08)
To evaluate the effect of Ridogrel enemas (Janssen Research Foundation, Beerse, Belgium) on disease activity and mucosal inflammatory mediators in patients with active left-sided ulcerative colitis. Eleven patients with active left-sided ulcerative colitis were evaluated in an open non-placebo-controlled pilot
Thromboxanes, prostaglandins, reactive oxygen metabolites and pro-inflammatory cytokines are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthesis inhibitor and receptor blocker, may have therapeutic benefits in ulcerative colitis. To investigate the anti-inflammatory profile
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.